Fidaxomicin to Prevent Clostridium Difficile Colonization

Withdrawn before enrolling · Phase 4 · Has a placebo group

Conditions studied: Clostridium Difficile Infection

In brief

The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.

Key facts

Study ID

NCT01552668

Run by

Washington University School of Medicine

People needed

0

Starts

2012-09-01

Expected to finish

2013-12-01

Last updated by the study team

2014-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old
• On broad spectrum antimicrobials
• Anticipated length of stay of > 48 hours after enrollment
• A non-ICU inpatient

You may not qualify if…

• Pregnant
• Expected to die within 7 days
• Have previously been enrolled in this trial or a trial of an investigational agent to treat CDI, and/or are on monotherapy with an antimicrobial generally considered not to increase the risk of CDI (vanc, macrolides, tetracyclines, trimethoprim/sulfamethoxazole, aminoglycosides, colistin, linezolid, nitrofurantoin, metronidazole)

Where it is running

• Washington University in St. Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.